Products Daratumumab was approved as an infusion product in the United States in 2015 and in many countries and the EU in 2016 (Darzalex). Structure and properties Daratumumab is a humanized IgG1κ monoclonal antibody with a molecular mass of approximately 148 kDa. It is produced by biotechnological methods. Effects Daratumumab (ATC L01XC24) has antitumor and … Daratumumab
Products Alemtuzumab is commercially available as a concentrate for the preparation of an infusion solution (Lemtrada). It was approved in 2014. Alemtuzumab was originally approved for leukemia treatment and marketed as MabCampath (approved in 2001). Structure and properties Alemtuzumab is a humanized IgG1 kappa monoclonal antibody to CD52 produced by biotechnological methods. It has a … Alemtuzumab
Products Omalizumab is commercially available as a powder and solvent for solution for injection (Xolair). It has been approved in many countries since 2006. Structure and properties Omalizumab is a recombinant, humanized monoclonal antibody with a molecular weight of approximately 149 kDa. Effects Omalizumab (ATC R03DX05) has antiallergic and antiasthmatic properties. The effects are based … Omalizumab
Products Cetuximab is commercially available as an infusion solution (Erbitux). It has been approved in many countries since 2003. Structure and properties Cetuximab is a recombinant chimeric (human/mouse) IgG1 monoclonal antibody. It is produced by biotechnological methods. Effects Cetuximab (ATC L01XC06) has antitumor and antiangiogenic properties. It is a specific antibody against the epidermal growth … Cetuximab
Products Pembrolizumab was approved as an infusion product in the United States in 2014 and in the EU and many countries in 2015 (Keytruda). Structure and properties Pembrolizumab is a humanized monoclonal antibody. It is an IgG4-κ immunoglobulin with a molecular weight of approximately 149 kDa. Effects Pembrolizumab (ATC L01XC18) has antitumor and immunomodulatory properties. … Pembrolizumab
Products Emicizumab was approved in the United States in 2017 and in the EU and many countries in 2018 as a subcutaneous solution for injection (Hemlibra). Structure and properties Emicizumab is a humanized and modified bispecific IgG4 monoclonal antibody that binds Factor IXa and Factor X. It is a human antibody. It has a molecular … Emicizumab
Products Erenumab (Aimovig) was the first agent from the group of CGRP inhibitors to be approved in 2018. Fremanezumab (Ajovy) and galcanezumab (Emgality) followed. Structure and properties CGRP inhibitors are humanized or human monoclonal IgG antibodies directed against calcitonin gene-related peptide (CGRP). Low-molecular-weight CGRP receptor antagonists (so-called Gepante) are in clinical development. Some agents have … CGRP Inhibitors
Products Pertuzumab is commercially available as a concentrate for the preparation of an infusion solution (Perjeta). It was approved in many countries in 2012. Structure and properties Pertuzumab is a recombinant humanized IgG1 monoclonal antibody. It was developed as a successor to trastuzumab (Herceptin). Effects Pertuzumab (ATC L01XC13) has cytostatic and antiproliferative properties. The effects … Pertuzumab
Products Blinatumomab is commercially available as an infusion product (Blincyto). It has been approved in the United States since 2014, in the EU since 2015, and in many countries since 2016. Structure and properties Blinatumomab is an antibody construct (fusion protein) of 504 amino acids with a molecular weight of approximately 54 kDa. It consists … Blinatumomab
Products Guselkumab was approved in the United States and the EU in 2017 and in many countries in 2018 as a solution for injection for subcutaneous use (Tremfya). Structure and properties Guselkumab is an IgG1λ monoclonal antibody produced by biotechnological methods. Effects Guselkumab (ATC L04AC16) has anti-inflammatory and immunosuppressive properties. The effects are due to … Guselkumab
Products Vedolizumab was approved in many countries in 2015 as a powder for a concentrate for the preparation of an infusion solution (Entyvio). In 2020, a prefilled pen and prefilled syringe were also registered. Structure and properties Vedolizumab is a humanized IgG1 monoclonal antibody with a molecular mass of 147 kDa. Effects Vedolizumab (ATC L04AA33) … Vedolizumab
Products Necitumumab was approved as an infusion solution in the United States in 2015 and in the EU in 2016 (Portrazza). Necitumumab has not yet been registered in many countries. Structure and properties Necitumumab is a recombinant human IgG1 monoclonal antibody. It is produced by biotechnological methods. Effects Necitumumab has antitumor, antiproliferative, and antiangiogenic properties. … Necitumumab